Flora Growth (FLGC) Competitors $0.65 -0.02 (-2.84%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.68 +0.03 (+4.15%) As of 03/28/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FLGC vs. CTOR, VNRX, AADI, HOWL, IMMX, IPSC, ITRM, OKYO, VRCA, and OTLKShould you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include Citius Oncology (CTOR), VolitionRx (VNRX), Aadi Bioscience (AADI), Werewolf Therapeutics (HOWL), Immix Biopharma (IMMX), Century Therapeutics (IPSC), Iterum Therapeutics (ITRM), OKYO Pharma (OKYO), Verrica Pharmaceuticals (VRCA), and Outlook Therapeutics (OTLK). These companies are all part of the "pharmaceutical products" industry. Flora Growth vs. Citius Oncology VolitionRx Aadi Bioscience Werewolf Therapeutics Immix Biopharma Century Therapeutics Iterum Therapeutics OKYO Pharma Verrica Pharmaceuticals Outlook Therapeutics Flora Growth (NASDAQ:FLGC) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk. Does the media prefer FLGC or CTOR? In the previous week, Flora Growth had 2 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Flora Growth and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.93 beat Flora Growth's score of 0.03 indicating that Citius Oncology is being referred to more favorably in the news media. Company Overall Sentiment Flora Growth Neutral Citius Oncology Positive Does the MarketBeat Community believe in FLGC or CTOR? Flora Growth received 14 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 60.00% of users gave Flora Growth an outperform vote. CompanyUnderperformOutperformFlora GrowthOutperform Votes1560.00% Underperform Votes1040.00% Citius OncologyOutperform Votes1100.00% Underperform VotesNo Votes Which has preferable earnings and valuation, FLGC or CTOR? Citius Oncology has lower revenue, but higher earnings than Flora Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlora Growth$59.51M0.21-$57.04M-$1.32-0.49Citius OncologyN/AN/A-$21.15MN/AN/A Is FLGC or CTOR more profitable? Citius Oncology has a net margin of 0.00% compared to Flora Growth's net margin of -30.99%. Citius Oncology's return on equity of -43.67% beat Flora Growth's return on equity.Company Net Margins Return on Equity Return on Assets Flora Growth-30.99% -268.17% -57.51% Citius Oncology N/A -43.67%-9.74% Which has more risk & volatility, FLGC or CTOR? Flora Growth has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.63, meaning that its share price is 163% less volatile than the S&P 500. Do insiders & institutionals have more ownership in FLGC or CTOR? 36.0% of Flora Growth shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 13.0% of Flora Growth shares are held by company insiders. Comparatively, 4.6% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer FLGC or CTOR? Flora Growth currently has a consensus price target of $5.00, indicating a potential upside of 669.23%. Citius Oncology has a consensus price target of $3.00, indicating a potential upside of 351.13%. Given Flora Growth's higher possible upside, equities analysts plainly believe Flora Growth is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCitius Oncology beats Flora Growth on 8 of the 15 factors compared between the two stocks. Remove Ads Get Flora Growth News Delivered to You Automatically Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLGC vs. The Competition Export to ExcelMetricFlora GrowthPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.63M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.497.2623.6018.74Price / Sales0.21218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.836.386.894.23Net Income-$57.04M$142.34M$3.20B$247.47M7 Day Performance4.84%-5.15%-3.06%-2.29%1 Month Performance-13.85%-7.55%1.52%-5.81%1 Year Performance-71.86%-11.06%9.37%-0.96% Flora Growth Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLGCFlora Growth3.1686 of 5 stars$0.65-2.8%$5.00+669.2%-71.9%$12.63M$59.51M-0.49280Earnings ReportShort Interest ↓CTORCitius OncologyN/A$0.71+14.5%$3.00+322.5%N/A$50.80MN/A0.00N/ANews CoverageGap UpVNRXVolitionRx1.8251 of 5 stars$0.55-0.4%$3.75+584.3%-27.3%$50.78M$1.29M-1.5280Analyst ForecastNews CoverageAADIAadi Bioscience1.2705 of 5 stars$2.05+4.6%$1.67-18.7%-18.4%$50.63M$25.07M-0.9040HOWLWerewolf Therapeutics2.7007 of 5 stars$1.12-0.9%$9.00+703.6%-84.1%$50.21M$1.89M-0.7340IMMXImmix Biopharma2.7322 of 5 stars$1.82+1.1%$7.00+284.6%-44.6%$50.07MN/A-2.149Earnings ReportNews CoverageIPSCCentury Therapeutics2.3043 of 5 stars$0.58+5.2%$5.00+756.6%-87.7%$49.63M$6.59M-0.32170Analyst ForecastAnalyst RevisionITRMIterum Therapeutics2.0763 of 5 stars$1.43-0.7%$5.00+249.7%-18.2%$49.45MN/A-1.0910Positive NewsOKYOOKYO Pharma3.2149 of 5 stars$1.42+5.2%$7.00+393.0%-9.4%$48.05MN/A0.007Short Interest ↓Positive NewsGap UpVRCAVerrica Pharmaceuticals4.2319 of 5 stars$0.52-6.4%$9.50+1,719.6%-92.7%$47.92M$7.57M-0.2940OTLKOutlook Therapeutics1.5479 of 5 stars$1.50-1.0%$10.20+582.3%-88.9%$47.87MN/A-0.2020Positive News Remove Ads Related Companies and Tools Related Companies CTOR Competitors VNRX Competitors AADI Competitors HOWL Competitors IMMX Competitors IPSC Competitors ITRM Competitors OKYO Competitors VRCA Competitors OTLK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLGC) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flora Growth Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flora Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
